In breast cancer-induced bone pain through the inoculation of Walker 256 cells into Wistar rats, topical XZP mitigated bone cancer-related nociceptive behaviour by inhibiting the PAR2/TRPV1 signalling via a reduction in PKA, PKC-γ, PAR2, and TRPV1 levels, alongside trypsin, IL-1β, and TNF-α serum levels. Here, TNF is linked to bone cancer.